Media coverage about Tetraphase Pharmaceuticals (NASDAQ:TTPH) has been trending somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tetraphase Pharmaceuticals earned a news sentiment score of 0.05 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 47.5083634628041 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news articles that may have effected Accern’s analysis:
Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded up 0.87% on Friday, hitting $5.83. 703,887 shares of the company’s stock were exchanged. The company’s market cap is $297.64 million. Tetraphase Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $9.93. The company’s 50-day moving average price is $6.86 and its 200-day moving average price is $7.12.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.07). Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The company had revenue of $1.59 million for the quarter, compared to analyst estimates of $1.54 million. During the same period in the previous year, the business posted ($0.47) EPS. The firm’s quarterly revenue was up 28.2% compared to the same quarter last year. Analysts forecast that Tetraphase Pharmaceuticals will post ($2.91) earnings per share for the current year.
TTPH has been the subject of a number of analyst reports. BMO Capital Markets reissued an “outperform” rating and set a $13.00 target price (up previously from $12.00) on shares of Tetraphase Pharmaceuticals in a research report on Wednesday, July 26th. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 6th. BidaskClub raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. Piper Jaffray Companies began coverage on shares of Tetraphase Pharmaceuticals in a research report on Monday, August 28th. They set an “overweight” rating and a $14.00 target price for the company. Finally, ValuEngine cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $12.96.
TRADEMARK VIOLATION NOTICE: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2017/10/27/tetraphase-pharmaceuticals-ttph-receives-daily-news-impact-score-of-0-05.html.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 17,500 shares of Tetraphase Pharmaceuticals stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $6.00, for a total value of $105,000.00. Following the completion of the transaction, the insider now owns 17,500 shares of the company’s stock, valued at $105,000. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 5.50% of the company’s stock.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.